Table 4 Estimated prevalence in the present study compared to the incidence (in 100,000) as reported by Khan et al., 2017 for each MPS type
From: Estimated prevalence of mucopolysaccharidoses from population-based exomes and genomes
MPS type | Gene | This study (max.–min.) | Khan et al. 2017 (max.–min.) |
|---|---|---|---|
MPS I | IDUA | 7.10–2.48 | 3.62–0.11 |
MPS II | IDS | 0.0108–0.00013 | 2.16–0.1 |
MPS IIIA | SGSH | 2.36–0.41 | 1.62–0.08 |
MPS IIIB | NAGLU | 1.53–0.37 | 0.72–0.02 |
MPS IIIC | HGSNAT | 1.57–0.11 | 0.42–0.03 |
MPS IIID | GNS | 0.46–0.05 | 0.10–0.09 |
MPS IVA | GALNS | 2.36–0.25 | 1.30–0.15 |
MPS IVB | GLB1 | 1.68–0.46* | 0.14–0.01 |
MPS VI | ARSB | 1.12–0.18 | 7.85–0.02 |
MPS VII | GUSB | 1.14–0.21 | 0.29–0.02 |
MPS IX | HYAL1 | 0.44–0.11 | NA |